Heat therapy zaps nasal nerves to ease stuffy nose

NCT ID NCT06599736

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a procedure called RhinAer that uses heat to treat the nerves in the nose for people with chronic rhinitis (long-term stuffy or runny nose). Researchers want to see if it reduces inflammation and improves symptoms like cough and post-nasal drip. About 25 adults aged 22 to 85 with at least 12 months of rhinitis are taking part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 25 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Mar 2026

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

22 to 85 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age 22 to 85 years (inclusively). 2. Willing and able to provide informed consent. 3. Willing and able to comply with the patient-specific requirements outlined in the study protocol. 4. Presenting to the ENT office seeking evaluation and/or treatment for chronic rhinitis (allergic or nonallergic) of at least 12 months duration 5. Willing to undergo the RhinAer procedure 6. Has a baseline rTNSS symptom score of ≥6 at time of screening 7. If on anticoagulation therapy, anticoagulant medications can be withheld during the perioperative period (at least 3-day window pre- and post-procedure). 8. Has been diagnosed with either allergic or non-allergic chronic rhinitis and meet the following criteria: * a. Allergic rhinitis: diagnosed with perennial (non-seasonal) allergic rhinitis and has demonstrated sensitization to specific allergens through skin prick testing, specific IgE blood testing, or other allergy testing methods, confirming the allergic nature of their rhinitis within the past 24 months. OR -b. Nonallergic rhinitis: diagnosed with nonallergic rhinitis with demonstration of a negative skin prick testing, specific IgE blood testing, or other allergy testing methods, confirming the nonallergic nature of their rhinitis within the past 24 months. Exclusion Criteria: 1. Anatomic obstructions in the nasal passage(s) that in the investigator's opinion limits access to the posterior nasal nerve treatment area. 2. Has seasonal rhinitis symptoms. 3. Current or recent use of biologic therapy within past 3 months. 4. History of chronic epistaxis or has had episodes of significant nose bleeds in the past 3 months. 5. Known or suspected allergies or contraindications to the anesthetic agents and/or antibiotic medications to be used during the study procedure. 6. Known or suspected to be pregnant or is lactating. 7. Has any condition resulting in a predisposition to excessive bleeding (e.g., hereditary hemorrhagic telangiectasia \[HHT\]). 8. Has diagnosis of rhinitis medicamentosa, an active nasal or sinus infection or has a history of 'dry eye.' 9. Has had previous procedure or surgery for chronic rhinitis (e.g., PNN ablation). 10. Has had a nasal or sinus surgical procedure in the past six (6) months. 11. Currently participating in another clinical research study or has participated in an interventional study within the past 3 months. 12. Has a planned adjunctive procedure at the time of the study procedure or within the 6-month study follow-up period 13. Other medical conditions which in the opinion of the investigator would predispose the patient to poor wound healing, increased surgical risk, or poor compliance with the requirements of the study.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Allergic chronic rhinitis are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Colorado ENT & Allergy

    Colorado Springs, Colorado, 80923, United States

  • University of Cincinnati

    Cincinnati, Ohio, 45267, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.